Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Latvia

Marie Skłodowska-Curie Action · Running

RegrOssBio Injectable biomimetic octacalcium phosphate based composites with antibacterial action for implant re-ossteointegration

Coordinator
Rigas Tehniska Universitate, Latvia
Runs
1 August 2023 to 31 July 2025
Status
Running
EU funding
€162k
Total cost
—
Partners
2 organisations in 2 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101106882

What the project is doing

In the project's own words, from its summary on CORDIS.

With increase of global dental implant industry, perimplantitis became an emerging problem worldwide, affecting up to 43% of the placed implants. Periimplantitis is caused by pathogenic microorganisms,that adhere to the implant surface triggering imflammation and bone destruction, eventally leading to implant loss in half of the cases. The overall aim of periimplantitis treatment is re-osteointegration of implant with surrounding bone, that can be achieved only in case of complete control over infection The existing treatment approaches are not able to provide efficient decontamination of the implant surfaces, while effectiveness of the existing local antibiotic delivery systems is questionable.

The aim of this project is to develop biomimetic injectable CaP-based pastes with antibacterial and osteogenic properties for periimplantitis treatment. We will utilize biocompatible materials, such as octacalcium phosphate (OCP) and natural hydrogels (hyaluronic acid and functionalized gelatin) that closely resemble to the composition of inorganic and organic components of the bone extracellular matrix. They will serve as versatile platforms for local delivery of antibiotics such as Metronidazole and Doxyciсline or antimicrobial nanoparticles into the peri-implant pockets after mechanical removal of the bacterial biofilm.

We hypothesize that these materials will offer control over infection in peri implant area and subsequent cellular functions and may have a great potential for implant re-osteointegration. To date, antibacterial formulations of bone graft materials, targeting peri-implant oral microflora are not available in the market. The obtained innovational products, designed according to the Principles of Good Manufacturing will have optimized composition and handling properties to be used straightforward at the chairside in dental office, without additional invasive surgical manipulations.

Topics

Who is involved

OrganisationCityCountryRole
Rigas Tehniska UniversitateRigaLatviaCoordinator
Aristoteleies Katartiseis Aksiologiseis Pistopoihseis Anonimi EtairiaThessalonikiGreeceAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI